The field of cancer care has evolved over the past 20 years with the development of more aggressive cancer screening programs, improvement in diagnostic testing and more effective treatment options, including the incorporation of novel targeted therapies. As a result, cancer death rates are gradually declining while cancer survivorship is steadily rising. However, these benefits are offset by long term adverse effects. Among them, cardiotoxicity is a leading cause for late morbidity and mortality. While conventional chemotherapy has been known for decades to induce detrimental effects on the heart and peripheral vasculature, the novel agents might also have harmful off-target consequences. 

Read More 


Dr. Yahalom is an Attending Radiation Oncologist and Member, Memorial Sloan-Kettering Cancer Center...

Read more



The Committee

Baruch Brenner
Zaza Iakobishvili
Ran Kornowski
Pia Raanani
Rinat Yerushalmi

Read More

Tel Aviv Cityscape